|
| (S)-MEPHENYTOIN Basic information |
| (S)-MEPHENYTOIN Chemical Properties |
Melting point | 135-138 °C | density | 1.154±0.06 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | DMSO: soluble | form | solid | pka | 8.07±0.70(Predicted) | color | off-white |
Hazard Codes | Xn | Risk Statements | 22-36/37/38 | Safety Statements | 26-36 | WGK Germany | 2 | HS Code | 29332100 |
| (S)-MEPHENYTOIN Usage And Synthesis |
Chemical Properties | White Crystalline Solid | Uses | S-Mephenytoin has been used as a CYP2C19 substrate for the analysis of cytochrome P450 metabolism. S-Mephenytoin has also been used as probe substrates for LC/MS-based analysis of relative activity factor (RAF). | Uses | (S)-Mephenytoin can be used as an anticonvulsant agent. | Definition | ChEBI: (S)-Mephenytoin is an imidazolidine-2,4-dione. | Biological Activity | (s)-mephenytoin is an anticonvulsive drug which is metabolized by n-demethylation and 4-hydroxylation (of the aromatic ring). (s)-mephenytoin is a substrate of the cytochrome p450 (cyp) isoform cyp2c19, also known as mephenytoin 4-hydroxylase [1].cyp2c19 is the main mephenytoin 4-hydroxylase in humans implicated in metabolizing a variety of therapeutic agents, such as omeprazole, proguanil, diazepam, propranolol, citalopram, imipramine, and certain barbiturates [2]. | Biochem/physiol Actions | CYP2B6 & CYP2C19 substrate. Methenytoin isomer. Anticonvulsant; antiepileptic. | in vitro | in the presence of cytochrome b5, the km value for s-mephenytoin was 1.25 mm with all five purified cytochrome p-450s preparations, and vmax values were 0.8-1.25 nmol of 4-hydroxy product formed per min/nmol of p-450 [1]. | references | [1] shimada t, misono k s, guengerich f p. human liver microsomal cytochrome p-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. purification and characterization of two similar forms involved in the reaction[j]. journal of biological chemistry, 1986, 261(2): 909-921. [2] ferguson r j, de morais s m f, benhamou s, et al. a new genetic defect in human cyp2c19: mutation of the initiation codon is responsible for poor metabolism of s-mephenytoin[j]. journal of pharmacology and experimental therapeutics, 1998, 284(1): 356-361. |
| (S)-MEPHENYTOIN Preparation Products And Raw materials |
|